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Abstract 
A concerted effort to sequence matched primary and metastatic tumours is vastly improving our 
ability to understand metastasis in humans. Compelling evidence has emerged that supports 40 
the existence of diverse and surprising metastatic patterns. Enhancing these efforts is a new 
class of algorithms that facilitate high-resolution subclonal modelling of metastatic spread. Here 
we summarise how subclonal models of metastasis are influencing the metastatic paradigm.      
 
Introduction 45 
For the vast majority of patients that die from solid malignancies, lethality can be directly traced 
to the propensity of their tumour cells to metastasize. Paget’s seminal seed and soil hypothesis 
proposed that the colonization of distant sites by primary seed tumour cells is dependent on a 
compatible environment in the secondary soil site (1). Developments of this central idea over 
the years has led to the prevailing view that metastases are founded by rare single cells that 50 
escape from the primary site. A key advantage of this view is that it provides an explanation for 
the relative rarity of clinical metastasis formation in the general cancer population.  
 
A body of evidence has subsequently accumulated that supports this model of tumour 
dissemination. Some of the early works include a study of spontaneously arising lung 55 
metastases in mouse models of melanoma, where cells uniquely tagged with random irradiation 
induced karyotypic markers unequivocally indicated that metastases originated from a single 
progenitor cell (2). Follow-on experiments showed that when mixtures of two distinct melanoma 
cell lines were injected intravenously, subsequent lung metastases were derived from only one 
line and not admixtures of the two cell lines (3). 60 
 
More recently, models of human metastasis have been updated, especially with regard to timing 
of spread (4). Largely responsible for this shift is the application of next-generation sequencing 
to matched primary and metastatic samples. By identifying sets of shared and private mutations, 
sample relatedness can be observed and an approximate evolutionary relationship determined. 65 
Studies of human colorectal cancer (5), pancreatic cancer (6), melanoma (7) and 
neuroblastoma (8) have shown that spread can occur late in the evolution of the primary 
disease, revealing a linear evolutionary relationship between primary and metastasis. 
Conversely, in renal cancer (9), metastatic progression has been shown to occur early, with 
both primary tumour and metastasis having private mutations and thus evolving in parallel. 70 
However, follow-up studies in pancreatic (10) and other cancers (11) show examples of both 
early and late spread, suggesting that timing patterns are not necessarily tumour specific. 
  
Studies across multiple metastases from the same patient have also revealed that 
asynchronous spread can occur from primary to multiple distant metastatic sites in colorectal 75 
cancer (11) as well as seeding from metastatic to secondary metastatic site in a cascading 
manner in prostate cancer (12), ovarian cancer (13) and pancreatic cancer (10). 
 
One limitation of these studies is that the clonal composition of each sample is determined using 
the presence or absence of private and shared mutations. This type of modelling does not allow 80 
estimation of clonal frequencies – vital for accurate evolutionary reconstruction and identification 
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of more than two clones per sample. In an attempt to adopt a more detailed modelling strategy, 
algorithms have been developed that model the clonal composition within a tumour using 
mutation variant allele frequencies. These algorithms have vastly improved our ability to model 
and understand metastatic spread. The first use of such an algorithm appeared in a study of 85 
primary breast cancers where it was used to accurately identify the clonal makeup of a tumour 
and infer the evolutionary history of its clones (genetically distinct populations of tumour cells) 
(14). Since then, a rapidly developing field has emerged that uses high-coverage exome, 
capture, amplicon and/or whole-genome tumour sequence data to trace clone lineages and infer 
phylogenetic relationships within and between lesions from individual patients (15, 16).  90 
 
A subset of recent studies have used these algorithms to infer the evolutionary relationship of 
clones in matched primary and metastatic samples (17-26), revealing patterns of metastasis 
only observable using this type of quantitative analysis. A recent review has outlined the 
implications of these studies on treatment, including a summary of the potential underlying 95 
genetic determinants of spread (27). Here we focus specifically on how subclonal modelling of 
multiple samples from the same individual has shaped our understanding of metastasis in 
humans.  
 
 100 
Subclonal modelling of metastasis 
By comparing the constituent subclonal mutations between pairs of primary and metastatic 
samples it is possible to derive the ancestral relationships between tumour clones rather than 
between tumour samples. This type of modelling has allowed confirmation of existing patterns of 
metastasismetastasic spread at increased (subclonal) resolution, and has yielded new insights 105 
into the patterns and timing of tumour cell spread which we articulate below.  
 
Timing of spread 
Seeding from an ancestral clone early during disease development (Figure 1a), results in a 
branched evolution pattern, where primary and metastasis evolve in a “parallel” manner (28). 110 
This has been shown at subclonal resolution in two lung cancer cases (22), two glioblastoma 
cases (26), one ovarian case (17), seven prostate cases (18, 29), as well as in mouse models, 
where evolutionary analysis of skin cancer demonstrated that the majority of tumours adopt a 
parallel mode of evolution (30). Much debate exists, however, whether particular tumour types 
have a dominant mode of evolution in humans. Spread occurring late in the evolution of the 115 
primary tumour in a linear fashion (Figure 1b) has been observed in one oral cancer case (25), 
eight melanoma cases (24), and four glioblastoma cases (in these cases from residual tumour 
cells) (26). While sample sizes across these studies are not yet sufficient to determine whether 
certain tumour types are enriched for late or early spread, examples of both have been seen in 
a study of eighty-two patients with brain metastases originating from various primaries (23), as 120 
well as across eleven cases of head and neck cancer (19). 
 
Seed composition 
4 
All tumour types studied at subclonal resolution mentioned in this review showed at least one 
example of monoclonal seeding where a single clone escapes the primary to found a metastatic 125 
deposit (Figure 1c). 
 
New data in mouse models of cancer metastasis have challenged the predominant monoclonal 
model of how metastases are constituted positing that some metastases are comprised of 
mixtures of distinct tumour clones seeded in a polyclonal manner (31-33). Furthermore, it has 130 
also been argued that clones present in polyclonal mixtures are not necessarily indifferent to 
one another, but may actually cooperate to seed a secondary lesion, suggesting that mutual 
interclonal cooperation between distinct clones exists (34). The evidence for such oncogenic 
cooperation in different model systems has recently been extensively covered in an excellent 
review (35). 135 
 
The key distinguishing feature required to confirm the existence of polyclonal seeding in bulk 
sequencing of human samples is the presence of subclonal clusters of mutations across 
multiple tumours from distinct locations. A mutation is considered subclonal if it appears in only 
a fraction of the tumour cells in a sample. Sets of mutations appearing subclonally in two or 140 
more metastases can arise under two potential scenarios: (1) the same sets of mutations occur 
independently in each sample; (2) two distinct founder cells containing the sets of mutations 
spread to each location together. While convergent evolution could give weight to scenario 1, it 
is extremely unlikely statistically given the sizeable sets of subclonal mutations observed in the 
studies discussed here. Therefore, scenario 2 can be the only real explanation for these 145 
subclonal clusters. It is this reasoning that has allowed the determination of the existence of 
polyclonal seeding in humans.  
 
Many of the studies discussed here have gone a step beyond subclonal clustering and inferred 
the evolutionary relationship between clones. This process facilitates finer understanding of 150 
polyclonal seeding and begins to help us determine if the polyclonal spread occurs 
synchronously with both cells transiting in unison, or asynchronously with multiple waves of 
spread to the same location. Although evidence is yet to accumulate to unequivocally determine 
synchronicity, the clonal evolution trees determined from multiple studies tend to favour one or 
the other.    155 
 
Synchronous polyclonal seeding is a plausible explanation for the patterns of spread observed 
in six separate studies across five tumour types: oral, breast, glioblastoma, melanoma and 
prostate (Figure 1d). In these studies, similar mixes of clones were detected in multiple samples 
from the same individual: Wood et al. reconstructed the clonal evolution of a matched oral 160 
primary and metastasis in patient PG030, showing that the same mix of clones was present in 
both samples (25); Murtaza et al observed two subclonal mutation clusters present at varying 
frequencies across five distant metastatic sites from a single breast cancer patient (21); two 
patients (C and E) showed evidence of polyclonal seeding in a study of melanoma (24); two 
cases of glioblastoma revealed clusters of mutations present at subclonal fractions in both 165 
primary and recurrent disease (26) and, two separate studies into prostate cancer revealed 
multiple cases of polyclonal seeding (18, 29). While it is feasible that the mix of clones observed 
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across these cases could have arisen asynchronously, evidence seen in studies of circulating 
tumour cell clusters lends weight to a synchronous model of spread: for example, a recent study 
of clusters of circulating tumour cells versus single cells showed that cell clusters had up to 50-170 
fold increased metastatic potential compared to single cells (36). Interestingly, however, in a 
study of 86 brain metastasis cases arising from various primary tumours, no evidence of 
polyclonal seeding was found (23) even though the authors explicitly searched for it. These 
differences could be attributed to the metastatic niche, whereby the blood-brain barrier 
prevented clusters of cells transiting but allowed single cell spread. This suggests that the ability 175 
for multiple clones to colonise a site could be heavily dependent on the metastatic niche.  
 
Despite the preference for a synchronous model of spread, asynchronous polyclonal seeding 
has been shown to be a more likely explanation for at least two patients from the 
aforementioned prostate studies (Figure 1d) (18, 29). In patient 177 from Hong et al. (29), a 180 
combination of unusual mutant allele frequency patterns combined with structural variant allele 
frequencies lead to the most likely explanation of the polyclonal makeup of a metastasis being 
an early spread from the primary tumour, followed by a late spread of a further evolved clone 
(Figure 1c). In patient A32 from Gundem et al., a left supraclavicular lymph node was seeded 
twice from the primary tumour. In the first wave of metastatic seeding, all 4 of the metastatic 185 
sites in this patient were seeded with a particular clone, however in a subsequent round of 
spread, a second distinct metastasizing clone spread to the left supraclavicular lymph node only 
and not the other three metastatic sites. These findings raise important questions as to whether 
some tumour clones act as pathfinders’ colonizing distant sites, which then act as beacons to 
attract subsequent waves of metastatic colonization in the nascent metastatic niche. Properties 190 
of the metastatic niche itself are also likely to contribute to metastatic subclonal seeding and 
expansion, as evidenced by patient A32. They also clearly suggest that for some patients, at 
least, removal of the primary tumour even after distant metastases have already been detected 
may still be clinically warranted as the primary tumour may continue to serve as an incubator of 
further metastatic tumour cell dissemination. This concept is now supported by a growing body 195 
of clinical evidence suggesting that treatment of primary tumours in patients with synchronous 
metastases can provide clinical benefits, including improvements in overall survival (37-40). 
Further along these lines, one could postulate that polyclonal seeding may occur more often at 
terminal disease stages where natural defence mechanisms are strained, facilitating easier 
colonization by multiple tumour clones. 200 
 
Seed source 
Subclonal modelling of multiregional of multiregional primary prostate tumour samples, allowed 
Hong et al. (29) to precisely pinpoint the clone that gave rise to a distant metastasis (Figure 1d). 
Furthermore, by defining each clone in the primary, they were able to interrogate its presence in 205 
circulating tumour DNA and found that in addition to the (expected) detection of metastatic 
clones, clones (presumed) exclusive to the primary tumour were also detected, despite the 
primary tumour being removed two years prior. These clones had not seeded any clinically 
obvious metastases, strongly implying that all clones had colonised distant sites, some occult. 
 210 
6 
As well as seeding from the primary, cells from one metastasis can seed another metastasis, 
resulting in what is known as an evolutionary cascade (Figure 1d). This phenomenon has been 
seen at subclonal resolution from lymph node to distant metastasis in mouse models of skin 
cancer (30), single cases of human breast cancer (21) and melanoma (24), and multiple 
prostate cases (18, 29). In one of these prostate cases, cross-metastatic site seeding appeared 215 
to occur directly in response to the onset of targeted treatment, with marked remodelling of the 
original subclonal composition at an iliac crest metastatic site within 12 weeks of the patient 
starting androgen deprivation therapy. Similar subclonal remodelling has also been shown in 
response to chemotherapy in ovarian cancer (17) and leukemia (41). 
 220 
Detecting polyclonal seeding 
Patterns of polyclonal seeding can only be detected using algorithms that identify the subclonal 
makeup of multiple tumour samples from a given patient (42-46). While there are a number of 
different computational techniques for inferring subclonal structure, the majority of studies 
covered in this review have used a statistical clustering algorithm known as a Bayesian Dirichlet 225 
Mixture Model. Therefore, to illustrate how polyclonal seeding is detected, we adapt an example 
from Gundem et al. (18), see Figure 2. We look at two samples from patient A22, a bladder 
metastasis (G) and a pelvic lymph node metastasis (H). Firstly, using copy-number, tumour 
purity, and tumour ploidy, the mutant allele fraction of each mutation is converted to the fraction 
of tumour cells harbouring the mutation, represented as black dots in Fig. 2a, also known as the 230 
cancer cell fraction (for conversion details see Nik-Zainal et al. (14)). A Bayesian Dirichlet 
Mixture Model is then used to group mutations into clusters based on their frequencies in both 
samples (red shading, Fig. 2a). These clusters subsequently help define the distinct populations 
of cells that arose from clonal expansions during the evolution of the tumour. The cluster of 
mutations present in all tumour cells in both samples represents the founding clone (dark blue 235 
circle Fig. 2a). Clusters of mutations that are in tumour cells across both samples, represent 
founding cells of the metastases (dark blue and purple circles, Fig. 2a). Clusters that are unique 
to one of the two samples represent the clones that are emerging at each site (orange, light 
blue, and green circles, Fig. 2a, for simplicity two clones belonging to the same metastasis with 
the same ancestor are coloured green). The frequencies of the clusters combined with the 240 
pigeon-hole principle (14) can then be used reconstruct the most likely clonal evolution tree (Fig. 
2b). As the purple cluster is present at subclonal frequencies in both samples, both cells from 
this clone and cells from the ancestral clone (dark blue circle) must have founded the metastatic 
site G in a polyclonal manner. The resulting clonal makeup can be represented by colour coded 
nested ovals reflecting the evolutionary relationship between clones (Fig. 2c, white space 245 
represents normal cell admixture). Finally an overall schematic of the clonal spread can be 
derived (Fig. 2d). 
 
 
Discussion 250 
The application of whole-genome sequencing and new computational methods to multiple 
metastatic samples has enabled exciting insights into the process of metastatic seeding, the 
presence of polyclonal seeding being the most significant. However, there are now many open 
questions around the underlying mechanisms behind this observation. Do clones transit as 
7 
polyclonal clusters or as single cells? If as clusters, are they cooperating within the cluster to 255 
survive blood transit and eventual seeding of distant sites? Do they form clusters within the 
blood or within the primary tumour site?  
 
Some headway has been made through animal models of breast cancer, with a recent study 
showing that clusters of tumour cells have a much higher capacity to induce metastasis 260 
formation, despite being present at much lower frequency than single cells (36). Furthermore, 
tumour cell clusters did not form in the blood but rather appeared to form within the site of 
tumour cell inoculation. Another important question is whether and to what extent specific 
clones may be involved in establishing pre-metastatic niches conducive to subsequent waves of 
tumour cell inoculation. Evidence in favour of this is the observed extracellular vesicles secreted 265 
by tumour cells that can be sequestered by bone-marrow derived cells, enhancing their capacity 
to form a metastatic niche (47-49). Following-on, specific clones might also be able to modify 
the metastatic potential of surrounding less metastatic clones through transfer of metastatic 
extracellular vesicles, as has been recently demonstrated in animal models of breast cancer 
(50). Further application of subclonal modelling to this question in humans is likely to yield 270 
greater insight.  
 
The polyclonal seeding observed in multiple sites across the cases discussed in this review may 
be indicative of intimate crosstalk occurring between metastatic clones and suggests that 
targeted disruption of these interactions might be productive in obstructing metastasis formation. 275 
Certain patterns of metastasis may be targeted by particular treatment regimes. However, these 
insights are currently limited by the availability of samples, so predicting which pattern is likely to 
occur in a given tumour subtype is not yet feasible. Further studies incorporating the subclonal 
analysis of multiple primary and multiple metastases from individual patients are required to not 
only answer fundamental questions as to how tumour cells metastasize but also provide insights 280 
in to how this process may be disrupted. 
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Figure 1 – Examples of subclonal modelling of metastasis in human tumours. This figure 
summarises the findings of several recent studies that sequenced the DNA of matched primary 440 
and metastatic tissue from lung, breast, melanoma, and prostate cancer patients. In each case, 
mutations were used to infer the evolutionary history of the disease as a clonal tree, where each 
node in the tree represents a genetically distinct population of cells, or clone. A schematic of the 
clonal spread in each patient is shown, along with a simplified version of the clonal evolution 
tree reported in the original studies. a) A lung cancer patient (PP4) from the Paik et al. (22) that 445 
showed early metastasis to the brain, resulting in a branched clonal tree with parallel evolution 
of both primary and metastasis. b) A lung cancer patient (308) from Brastianos et al. (23) that 
showed late spread to the brain resulting in a linear clonal tree. c) A melanoma patient (H) from 
Sanborn et al. that showed a distant brain metastasis seeded from a single clone present in a 
leg lesion. d) left – a prostate cancer patient (177) from Hong et al. (29) showing an early and 450 
late spread of two clones to the ilium in an asynchronous polyclonal manner. Right – a prostate 
cancer patient (A32) from Gundem et al. (18) showing the spread of two clones to two separate 
metastatic locations in a synchronous manner. e) A prostate cancer patient (299) from Hong et 
al. (29) with multiple regions of the primary sequenced showing a single, extraprostatic clone as 
the source of the shoulder metastasis. f) A breast cancer patient from Murtaza et al. (21) 455 
showing a cascade of spread from primary to brain metastasis, then brain to ovary. 
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Figure 2 – Detecting polyclonal seeding. This figure illustrates how polyclonal seeding can be 
detected using a Dirichlet Mixture modelling approach (see main text for a detailed description). 460 
a) A density plot showing the cancer cell fractions of mutations (black dots) in two metastatic 
samples of a prostate patient. The red shading represents the posterior probability of a cluster 
as determined using a Dirichlet Mixture Model. The coloured circles show the defined mutation 
clusters. b) A clone tree where each node represents a tumour clone with a distinct genotype. 
The shaded ellipses show the clone membership for the samples from this patient. c) An “easter 465 
egg” plot showing clone membership and ancestry as a series of embedded ellipses. The size 
of the ellipses is approximately proportional to the number of cells in the sample from that clone. 
d) A schematic showing the clonal composition of the primary tumour and metastases.        
